• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Immuno-checkpoint inhibitors in metastatic esophago-gastric cancer.转移性食管胃癌中的免疫检查点抑制剂
J Thorac Dis. 2019 Mar;11(Suppl 3):S376-S380. doi: 10.21037/jtd.2018.12.71.
2
Parenteral nutrition during neoadjuvant chemotherapy for patients with non-metastatic gastric or esophago-gastric cancer to reduce postoperative morbidity (PERCOG): study protocol for a randomized controlled trial.新辅助化疗期间给予非转移性胃癌或食管胃癌患者肠外营养以降低术后发病率（PERCOG）：一项随机对照试验的研究方案
Trials. 2017 Dec 28;18(1):621. doi: 10.1186/s13063-017-2388-3.
3
Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma.组蛋白去乙酰化酶抑制剂用于克服转移性黑色素瘤对靶向治疗和免疫治疗的耐药性
Front Cell Dev Biol. 2020 Jun 17;8:486. doi: 10.3389/fcell.2020.00486. eCollection 2020.
4
Pembrolizumab for the treatment of gastric cancer.帕博利珠单抗治疗胃癌。
Expert Rev Anticancer Ther. 2018 Dec;18(12):1177-1187. doi: 10.1080/14737140.2018.1526084. Epub 2018 Oct 3.
5
Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials.局部晚期胃癌和食管胃结合部腺癌的新辅助化疗。随机试验的荟萃分析。
Int J Surg. 2018 Mar;51:120-127. doi: 10.1016/j.ijsu.2018.01.008. Epub 2018 Feb 20.
6
Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists.胃肠肿瘤的免疫肿瘤学：PD-1/PD-L1 拮抗剂的临床证据和新试验。
Crit Rev Oncol Hematol. 2018 Oct;130:13-26. doi: 10.1016/j.critrevonc.2018.07.001. Epub 2018 Jul 11.
7
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.选择转移性胃食管交界部癌症患者行胃切除术：临床和病理检查还不够。
Future Oncol. 2017 Oct;13(25):2265-2275. doi: 10.2217/fon-2017-0246. Epub 2017 Oct 4.
8
[Checkpoint Inhibitors in the Treatment of Upper Gastrointestinal Tract Tumors].[检查点抑制剂在上消化道肿瘤治疗中的应用]
Klin Onkol. 2017 Winter;30(Supplementum3):50-54.
9
Recurrence after surgery in esophago-gastric junction adenocarcinoma: Current management and future perspectives.食管胃交界腺癌术后复发：当前治疗及未来展望
Surg Oncol. 2016 Dec;25(4):355-363. doi: 10.1016/j.suronc.2016.08.003. Epub 2016 Aug 16.
10
[A Case of Esophago-Gastric Junctional Carcinoma with Intramural Invasion and Cervical Lymph Node Metastasis].[1例伴有壁内浸润和颈部淋巴结转移的食管胃交界腺癌]
Gan To Kagaku Ryoho. 2017 Nov;44(12):1677-1679.

本文引用的文献

1
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.帕博利珠单抗单药治疗既往治疗的晚期胃和胃食管结合部癌患者的安全性和疗效：Ⅱ期 KEYNOTE-059 临床试验。
JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013.
2
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.纳武利尤单抗联合伊匹单抗治疗错配修复缺陷/微卫星高度不稳定转移性结直肠癌的持久临床获益。
J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.
3
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.纳武利尤单抗治疗既往至少两种化疗方案治疗失败或不耐受的晚期胃或胃食管结合部腺癌患者（ONO-4538-12，ATTRACTION-2）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6.
4
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的总生存期
N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.
5
Reduced-dose ipilimumab with standard-dose pembrolizumab: is less more?
Lancet Oncol. 2017 Sep;18(9):1144-1145. doi: 10.1016/S1470-2045(17)30518-1. Epub 2017 Jul 17.
6
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.纳武单抗联合伊匹木单抗治疗转移性肾细胞癌的安全性和疗效：CheckMate 016研究
J Clin Oncol. 2017 Dec 1;35(34):3851-3858. doi: 10.1200/JCO.2016.72.1985. Epub 2017 Jul 5.
7
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.纳武利尤单抗联合伊匹木单抗作为晚期非小细胞肺癌的一线治疗方案（CheckMate 012）：一项开放标签的1期多队列研究结果
Lancet Oncol. 2017 Jan;18(1):31-41. doi: 10.1016/S1470-2045(16)30624-6. Epub 2016 Dec 5.
8
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.基于检查点抑制剂的免疫疗法的预测性生物标志物。
Lancet Oncol. 2016 Dec;17(12):e542-e551. doi: 10.1016/S1470-2045(16)30406-5.
9
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.实体瘤中的免疫检查点抑制剂联合疗法：机遇与挑战
Immunotherapy. 2016 Jun;8(7):821-37. doi: 10.2217/imt-2016-0002.
10
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.纳武利尤单抗单药治疗及纳武利尤单抗联合伊匹单抗治疗复发性小细胞肺癌（CheckMate 032）：一项多中心、开放标签、Ⅰ/Ⅱ期试验。
Lancet Oncol. 2016 Jul;17(7):883-895. doi: 10.1016/S1470-2045(16)30098-5. Epub 2016 Jun 4.

Immuno-checkpoint inhibitors in metastatic esophago-gastric cancer.

作者信息

Schena Marina, Battaglia Angelo F, Trogu Antonio

机构信息

Oncology and Onco-hematology Department, Ospedale Regionale Umberto Parini, Aosta, Italy.

出版信息

J Thorac Dis. 2019 Mar;11(Suppl 3):S376-S380. doi: 10.21037/jtd.2018.12.71.

DOI:10.21037/jtd.2018.12.71
PMID:30997225
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6424743/
Abstract
摘要